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Recently heparan sulfate was proposed as the host cell receptor for the dependovirus, adeno-associated virus type 2
(AAV2). We show that although heparan sulfate on the cell surface may contribute to the binding of AAV2 to permissive cells,
the amount of heparan sulfate on the cell surface as determined by flow cytometry using four different monoclonal antibodies
does not correlate with AAV2 binding to cells or recombinant AAV2 transduction efficiency. Experiments with either mutant
CHO cells or cells treated with chlorate to remove sulfate groups showed that sulfation was not absolutely required for
infection or binding: in the absence of cell surface sulfation, recombinant AAV2 was still able to be transduced in previously
permissive cells. Heparin is commonly used as a substitute in studies of the interaction between heparan sulfate and ligand,
and we demonstrate that the binding affinity of AAV2/heparin is low, with a Kd value of ;2.0 nM. A study of the direct
interaction between AAV2 and artificial glycosaminoglycans showed that a high degree of sulfation on heparin was critical
for the ability to bind AAV2 and compete rAAV2 transduction and that both O- and N-sulfate groups are required. Overall, our
data suggest that, as has been shown for other viruses, the presence of a high-affinity AAV2 receptor mediates AAV2
infection in addition to the low-affinity heparan sulfate binding. © 2000 Academic Press
l
b
(
n
s
rINTRODUCTION
Adeno-associated virus type 2 (AAV2), a member of the
dependovirus genus of the Parvoviridae, can replicate
efficiently in a wide range of human and nonhuman cells
with the addition of helper viruses, such as adenovirus or
herpesvirus (Siegl et al., 1985). However, there are cell
lines that, even in the presence of helper virus, are
nonpermissive for AAV2 replication, including the human
megakaryoblastic cell lines UT-7/Epo, MB-02, and MO7e
(Mizukami et al., 1996; Ponnazhagan et al., 1996). These
cell lines have reduced binding of virus to the cell sur-
face, and the identification of cell lines that apparently
lack a cell receptor for AAV2, together with the observa-
tions that AAV2 binding shows saturation kinetics and
trypsin treatment of cells can abolish AAV2 binding to the
cell surface, suggests that AAV2 uses a specific protein
receptor to mediate infection (Mizukami et al., 1996).
Recently, based upon heparin competition studies, en-
zymatic removal with heparinase, and data from mutant
CHO cells lacking heparan sulfate, cell surface heparan
sulfate proteoglycans have been proposed to act as a
receptor for AAV2 (Summerford and Samulski, 1998a). All
adherent cells express glycosaminoglycans (GAGs) on
their cell surface, with heparan sulfate being the most
ubiquitous cell surface GAG, commonly attached to a
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137low-molecular-weight protein core. Heparan sulfate itself
has been proposed as the initial attachment molecule for
a variety of cytokines, growth factors, and chemokines
(Moscatelli, 1987; Sadir et al., 1998; Hoogewerf et al.,
1997). Probably the best studied interaction is with basic
fibroblast growth factor (bFGF), which has shown that
although the biological response of cells to bFGF is
mediated through specific, high-affinity (K d 5 2;20 pM)
cell surface receptor (bFGFR) (Coughlin et al., 1988),
ow-affinity heparan sulfate binding is a prerequisite for
inding of bFGFR to its high-affinity receptor (FGFR)
Yayon et al., 1991). Similarly, interferon-g (IFN-g) and a
umber of other growth factors bind both to heparan
ulfate or related molecules and to a specific high-affinity
eceptor (IFN-gR) (Sadir et al., 1998).
The first viruses proposed to use heparan sulfate for
binding were herpes simplex virus 1 and 2 (HSV-1,
HSV-2) (WuDunn and Spear, 1989), and subsequently it
has been suggested that a number of other viruses use
heparan sulfate as an initial attachment molecule: cyto-
megalovirus (CMV) (Compton et al., 1993); human immu-
nodeficiency virus (HIV) (Patel et al., 1993; Ohshiro et al.,
1996); respiratory syncytial virus (Krusat and Streckert,
1997); dengue virus (Chen et al., 1997); pseudorabies
virus (Trybala et al., 1998); foot-and-mouth disease virus
(Baranowski et al., 1998); vaccinia virus (Chung et al.,
1998); Sindbis virus (Byrnes and Griffin, 1998; Klimstra et
al., 1998); and papillomavirus type 11 (Joyce et al., 1999).
However, even though removal of heparan sulfate from
cell membranes remarkably reduces the ability of HIV to
infect cells (Patel et al., 1993), it is now known that the
0042-6822/00 $35.00
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138 QIU ET AL.major cellular receptor for HIV is the CD4 molecule
(Sattentau et al., 1986), with chemokines like CCR3 and
CCR5 acting as coreceptors (Choe et al., 1996; Deng et
al., 1996). Similarly for HSV-1, although 10 years ago it
was suggested that heparan sulfate was the receptor for
HSV-1, more recently two high-affinity HSV receptors
were identified (Montgomery et al., 1996; Roller and
Rauch, 1998; Geraghty et al., 1998; Cocchi et al., 1998).
Prior to the identification of these receptors, it had also
been suggested that HSV may use the high-affinity FGFR
as a receptor (Kaner et al., 1990), analogous to the recent
proposal that AAV2 also uses FGFR as a coreceptor
(Qing et al., 1999). However, subsequent studies of HSV
binding demonstrated that the FGFR association was
artificial due to competition with heparan sulfate in me-
dium, and FGFR was not required for HSV infection
(Shieh and Spear, 1991; Muggeridge et al., 1992).
In this paper, we show that the presence of heparan
sulfate on the cell surface does not directly correlate with
either AAV2 binding or transduction efficiency of recom-
binant AAV2, although heparan sulfate may play a role in
AAV2 infection as a low-affinity attachment molecule.
The direct interaction of AAV2 with heparin-like mole-
cules is also studied in further detail.
RESULTS
Comparison of cell surface heparan sulfate, rAAV2
transduction, and AAV2 binding
A variety of different cell lines were tested by flow
cytometry using four different monoclonal antibodies to
T
Source of Monoclonal Antibodies a
Antibody Isotype Specificity
HepSS-1 IgM Heparan sulfate
mAb10E4 IgM Heparan sulfate
mAb615 IgM Heparan sulfate
mAb570 IgG2b Heparin
mAb2040 IgM Heparin/heparan sulfat
T
Comparison of Flow Cytometric Analysis with Four Different Monoc
CHO cell Amount of heparan sulfate mAb615
1 100% 111
gsE606 2.6-fold less sulfation 11
gsB618 15% 6
gsA745 0% 2
gsD677 0% 2
Note. rAAV transduction was performed with rAAV LcZ (m.o.i. 5
b-galactosidase and the number of transduced cells was determined. FACS an
(.0.9 log shift); 1, positive (.0.4 log shift); 6, weakly positive (,0.4 log shifheparin and/or heparan sulfate (Table 1). CHO-K1 cells
were positive by all four antibodies (Table 2), and the
mutant CHO cell lines, pgsA745 and pgsD677, with
known mutations leading to no heparan sulfate expres-
sion (Esko et al., 1985, 1988), were uniformly negative.
The cell line pgsE606, which has ;2.6-fold less sulfation
of the heparan sulfate (Bame and Esko, 1989), was also
positive by all four antibodies, but with decreased fluo-
rescence intensity. Cell line pgsB618, which expresses
only 15% of the normal concentration of heparan sulfate
(Esko et al., 1988), was weakly positive by monoclonal
mAb615 only, suggesting that analysis using mAb615 had
the greatest sensitivity, and fluorescence with this mono-
clonal antibody appeared to correlate with the actual
amount of heparan sulfate on the cell surface. All the
mutant cell lines, including those with no heparan sul-
fate, could be transduced by rAAV2, albeit with lower
transduction efficiencies for the cells with no heparan
sulfate expression (Fig. 1).
The monoclonal antibodies were also used to mea-
sure the amount of heparan sulfate on a variety of ad-
herent and suspension cell lines (Tables 3 and 4). Hepa-
ran sulfate could be detected on all the epithelial and
fibroblast cell lines using three of the monoclonal anti-
bodies (mAb10E, mAb615 and mAb570), but not by
HepSS-1 (Table 3): when HeLa S3 cells were cultured in
a spinner bottle instead of a stationary flask, heparan
sulfate could no longer be detected by monoclonal anti-
bodies HepSS-1 or mAb2040 (data not shown), suggest-
ing that these epitopes are variable depending on the
cell culture conditions. However, the efficiencies of wild-
either Heparin or Heparan Sulfate
Source Reference
Seikagaku American Kure and Yoshie, (1986)
Seikagaku American David et al. (1992)
Dr. Thorley-Lawson Ianelli et al. (1998)
Chemicon Fillit et al. (1996)
Chemicon Shibata et al. (1993)
ntibodies and rAAV2-LacZ Transduction of Mutant CHO Cell Lines
0 mAb10E4 HepSS-1 rAAV2 transduction (%)
11 1 55.3 6 8.4
1 6 52.3 6 7.5
2 2 5.3 6 1.5
2 2 9.7 6 2.5
2 2 1.8 6 0.8
orty-eight hours posttransduction cells were fixed and stained forABLE 1
gainstABLE 2
lonal A
mAb57
1
6
2
2
2
3.0). F
alysis: 111, strongly positive (.1.4 log shift); 11, moderately positive
t); 2, totally negative (no shift).
f -K1 cell
c
139INTERACTION BETWEEN HEPARAN SULFATE AND AAV2type infection (data not shown) or rAAV2 transduction
were unchanged. In contrast, although A431 cells had
abundant heparan sulfate on the cell surface as detected
by all monoclonal antibodies, there was reduced infec-
tion/transduction with AAV2.
Detection of heparan sulfate on hematopoietic cells
was much more variable (Table 4). Only one hematopoi-
etic cell line was found to be consistently negative by all
four monoclonal antibodies, MO7e, and this cell line has
also been shown to be nonpermissive for AAV2 infection
(Ponnazhagan et al., 1996). As noted with the mutant
CHO cell lines, mAb615 appeared to be the most sensi-
tive antibody.
FIG. 1. Transduction of mutant CHO cells with rAAV2-LacZ. Cells (5 3
or 48 h and then examined for b-galactosidase-positive cells. (A) CHO
ells.As many hematopoietic cell lines are nonpermissive
for adenovirus infection, cells were also tested for theirability to be transduced by rAAV2-GFP. Many hematopoi-
etic cells were nonpermissive for rAAV2 transduction,
even though heparan sulfate was detected on the cell
surface, and a relatively high m.o.i. was used for the
transduction (Table 4). To exclude the possibility that the
cells could not express the GFP, all cell lines were tested
by direct transfection of the GFP plasmid, and all con-
firmed that GFP could be detected (data not shown).
We also examined the relationship between the
amount of heparan sulfate on the cell surface and AAV2
binding to certain cell lines (Tables 3 and 4). AAV2 bind-
ing to 293 cells was less efficient than to HeLa, KB,
Hep-2 and CHO-K1 cells (data not shown), but all those
ells/well in a microtiter plate) were incubated LacZ r-AAV2 (m.o.i. 5 3)
s; (B) pgsE606 cells; (C) pgsB618 cells; (D) pgsD677 cells; (E) pgsA745104 ccells had a similar rAAV2 transduction efficiency. For
hematopoietic cells, there was again no direct correla-
A
o
140 QIU ET AL.tion with AAV2 binding and the presence of heparan
sulfate, with some cells (MEG-O1 and Jurkat) showing
little binding despite the presence of heparan sulfate.
However, there was little binding of AAV2 to cells with no
(MO7e cells) or low levels (less than a 0.9 log shift
compared to isotype control on FACS analysis) of hepa-
ran sulfate (HL60, KG-1, CEM, etc).
Blocking of AAV2 binding/transduction with
monoclonal antibodies
The monoclonal antibodies were also tested for their
ability to block both binding and rAAV2 transduction.
T
Flow Cytometric Analysis, LacZ-rAAV Transduction, and
Cell types mAb615 mAb570 mAb10E4
HeLa S3a 111 11 6
HeLa S3b 111 11 6
HeLa 111 11 11
KB 111 1 11
Hep-2 111 11 11
293 111 11 11
A431 111 1 1
Note. FACS and rAAV transduction assay was done as described in
AV2 in the presence or in the absence of noniodinated virus. Specific
f 100 times cold virus) and is shown relative to the value obtained w
a HeLa S3 cells cultured in spinner.
b HeLa S3 cells cultured in flask.
T
Flow Cytometric Analysis, rAAV-GFP Transducti
Cell types mAb615 mAb570 mAb10E4
Myeloid/erythromegakaryoblastoid cells
K562 111 1 1
TF-1 111 1 1
MEG-
O1 111 11 2
KG-1a 11 6 2
HEL 11 2 2
KG-1 1 1 6
U937 6 1 2
HL60 2 1 2
MO7e 2 2 2
Lymphoid cells
D1.1 111 1 1
Molt-3 111 11 2
Jurkat 111 1 2
CESS 11 1 11
Raji 11 1 6
CEM 1 11 2
RS 1 2 2
Note. FACS analysis and liquid binding assay as in Table 3. rAAV2-G
rAAV-GFP (m.o.i. 5 2.7), and 48 h later, positive cells counted in three different
value compared with KG-1a cells.There was no reduction in AAV2 transduction with mono-
clonal antibodies mAb 615, HepSS-1, or mAb10E. How-
ever, at high concentrations mAb570 was able to signif-
icantly reduce rAAV-LacZ transduction compared to an
IgG2b isotype control antibody (Fig. 2). Monoclonal anti-
body mAb570 was the only antibody that recognized an
epitope uniquely on heparin and has been shown to
block the interaction of anti-thrombin and heparin (Fillit et
al., 1996). Heparin itself is not a constituent of cell mem-
branes, but is a highly sulfated structural homologue of
heparan sulfate, and although the specific epitope for
mAb570 has not been specifically identified, this result
-Specific Binding of Adherent Cells and HeLa S3 Cells
HepSS-1
rAAV transduction
x 6 STD (%)
% AAV2 binding
(HeLa 5 100%)
2 52.7 6 6.4 122.4
1 52.0 6 7.5 119.3
6 50.7 6 9.0 100
2 45.0 6 5.0 69.5
1 35.0 6 5.0 74.7
6 41.0 6 3.6 27.9
6 7.7 6 2.5 119.4
. For the AAV2 binding assay 105 cells were incubated with iodinated
was obtained by subtracting the nonspecific binding (in the presence
a cells. Experiments were performed in triplicate.
AAV2 Specific Binding of Hematopoietic Cells
HepSS-1
% rAAV transduction
x 6 STD (%)
AAV2 binding
(KG-1a 5 100%)
11 52.0 6 11 162.6
6 0 63.7
2 0 10.4
2 5.2 6 1.5 100
2 0 14.9
2 0 18.0
2 0 9.7
2 0 26.0
2 0 17.6
2 1.1 6 0.7 58.6
2 10.5 6 2.9 80.0
2 5.0 6 1.1 34.0
1 0.8 6 0.5 127.4
1 2.7 6 0.7 126.8
2 1.1 6 0.9 25.9
2 1.2 6 0.8 30.6
nsduction was performed in microtiter wells: cells were infected withABLE 3
AAV2
Table 2
binding
ith HeLABLE 4
on, and
FP tra
fields by UV microscopy. AAV2-specific binding is shown as a relative
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141INTERACTION BETWEEN HEPARAN SULFATE AND AAV2suggested that relative sulfation may be important for
AAV2 interaction.
Effect of sulfation on AAV binding and rAAV2
transduction
For most of the heparin-binding viruses, sulfation on
the cell surface is critical for viral binding and infec-
tion, and the removal of sulfation by chlorate treatment
significantly reduces viral binding and infection
(Chung et al., 1998; Chen et al., 1997; Patel et al., 1993;
oyce et al., 1999). It is known that the addition of 10
M sodium chlorate to sulfate-free medium blocks
ellular ATP-sulfurylase and sulfate adenyl-trans-
erase activity and reduces sulfate incorporation into
AGs by up to 96% (Esko et al., 1988; Greve et al.,
988; Keller et al., 1989). Therefore, in order to look into
hether sulfation on the cell surface plays the same
ole in AAV2 binding and infection, HeLa and 293 cells
ere grown in sulfate-free medium for 4 days, and
AV2 binding and rAAV2-LacZ transduction were ex-
mined. The cells continued to grow with a normal
orphology indistinguishable from that of control cells
ultured in sulfate-supplemented medium (data not
hown). There was a two- to threefold reduction in
AV2 binding (Fig. 3A) and a three- to fivefold reduc-
ion in rAAV2-LacZ transduction efficiency (Fig. 3B) of
he cells grown in sodium chlorate medium, suggest-
ng that although sulfation contributed to AAV2 binding
FIG. 2. Inhibitory effect of monoclonal antibodies on rAAV2-LacZ
transduction. HeLa cell monolayers in microtiter wells were preincu-
bated with mAbs at 1 mg/ml (black bars), 10 mg/ml (white bars), and 100
mg/ml (gray bars) for 1 h at 37°C, washed, and incubated with AAV2-
LacZ (m.o.i. 5 1.5) for 1 h. After being further washed to remove
onadherent virus, the cells were incubated at 37°C and 48 h later cells
ere washed with PBS, fixed, and b-galactosidase stained, and the
positive blue cells were counted.nd infection, it did not appear to be a requirement for
nfection. pnhibition of AAV2 infection by blocking AAV2/heparan
ulfate interaction
Heparan sulfate contains both N- and O-sulfate moi-
ties, and to further investigate the relative roles of these
tructures in AAV2 binding, a series of selectively mod-
fied heparins and an artificial highly sulfated polysac-
haride, dextran sulfate (17% sulfation), were used to
lock rAAV2 transduction in competition experiments.
lthough heparin significantly reduced rAAV transduc-
ion, there was no effect using bovine heparan sulfate
which has relatively low sulfation (Chen et al., 1997)),
extran sulfate, O-desulfated heparin (ODSH), N-desul-
ated heparin (NDSH), or O- and N-desulfated heparin
CDSH) (Fig. 4).
These results were confirmed by studying the direct
inding of iodinated AAV2 to immobilized modified hep-
rins in a microtiter well. Although AAV2 bound to hep-
FIG. 3. Role of sulfation on cell surface in AAV2 binding and rAAV2
transduction. HeLa and 293 cells were cultured in sulfate-free Joklik
medium with 20 mM sodium chlorate plus 8% dialyzed FCS and the
control, plus 0.8 mM sodium sulfate. Forty-eight hours later, cells were
tested for AAV2 binding and rAAV2 transduction. (A) Desulfated cells
were incubated with iodinated AAV2 in the presence or in the absence
of cold virus, and specific binding was calculated by subtracting the
nonspecific binding in the presence of 100 times cold virus. The
binding was compared with the control (undesulfated cells). (B) Cells
were transduced by rAAV2 (m.o.i. 5 1.5) at 37°C for 1 h. Forty-eight
hours later, cells were fixed and b-galactosidase stained, and the
ositive blue cells were counted.
p
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142 QIU ET AL.arin, there was a very low level of binding to dextran
sulfate, heparan sulfate, and chondroitin sulfates (Fig. 5).
All the modified heparins showed significantly reduced
binding of AAV2, regardless of the modification of sulfate
groups. As in the competition studies there was little
binding of AAV2 to the highly sulfated dextran, indicating
that a high degree of sulfation (or charge density) itself is
not important for AAV2 binding and that the polysaccha-
ride structure of heparin/heparan sulfate contributes to
binding. In addition, both O- and N-sulfate groups appear
important for AAV2 binding/transduction.
Calculation of the binding affinity of AAV2 to heparin
To determine whether the binding of AAV2 to heparan
sulfate occurred with high or low affinity, the binding
affinity was calculated using heparin-conjugated BSA-
coated microtiter plates and different concentrations of
iodinated AAV2. The binding affinity was calculated both
by Scatchard analysis (Hulme and Birdsall, 1992; Scat-
chard, 1949) and by estimating the concentration of AAV2
that gave 50% specific binding (Fig. 6). The binding af-
finity of AAV2 binding to heparin was 1.7–2.5 nM AAV2
capsid.
DISCUSSION
In this study, we examined the binding of AAV2 to
different heparin structures in vitro and examined the
ability of different heparins, heparan sulfate, or antibod-
ies to block AAV2 infection and rAAV2 transduction. How-
FIG. 4. Inhibitory effect of glycosaminoglycans (GAGs) on rAAV2-
LacZ transduction. rAAV2-LacZ (m.o.i. 5 1.5) was mixed with different
GAGs to final concentration of 1 mg/ml (black bars), 10 mg/ml (white
bars), and 100 mg/ml (gray bars) at 37°C for 30 min, and the mixture
was added to HeLa cell monolayer on 96 microtiter wells. Forty-eight
hours later cells were washed with PBS, fixed, and b-galactosidase
stained, and the positive blue cells were counted. H: heparin; NDSH,
N-desulfated heparin; ODSH, O-desulfated heparin; CDSH, completely
desulfated heparin; DS, dextran sulfate; HS, heparin sulfate.ever, when mutant CHO cells were tested for AAV2 bind-
ing and rAAV2 transduction, in contrast to the previous
C
sreport in which the authors showed no transduction of
pgsD677 and low levels in pgsA745 (Summerford and
Samulski, 1998a), we were able to transduce both hepa-
ran sulfate-negative cell lines (Fig. 1 and Table 2). This
discrepancy may be partially explained by the difference
in calculating AAV2 transduction; in the previous paper
rAAV2 transduction was calculated by measuring the
total b-galactosidase activity in culture, rather than the
number of cells transduced. However, our data clearly
show that heparan sulfate-deficient CHO cells can be
transduced by rAAV2 to the 2–10% level, using a relatively
low multiplicity of infection (m.o.i. 5 3).
It was also previously suggested that the relative level
of heparan sulfate on the cell surface measured by flow
cytometry using mAb HepSS-1 correlated with the ability
of AAV2 to bind various cell lines in vitro (Summerford
and Samulski, 1998b). However, we were unable to con-
firm this finding: in HeLa S3 cells, the presence or ab-
sence of this epitope varied with culture conditions al-
though there was no change in permissivity to AAV2.
Previous studies have also shown that cell density and
culture conditions can affect the expression of the
HepSS-1 epitope on murine NIH3T3 cells (Kure and Yo-
shie, 1986).
For some cell lines such as A431 cells, which show
low transduction efficiency, it has been proposed that the
rate of conversion of ssDNA to transcriptionally func-
tional dsDNA is rate-limiting (Mah et al., 1998), due to the
formation of replicative dimers (Ferrari et al., 1996; Qing
et al., 1997) or circular intermediates (Sanlioglu et al.,
1999). Therefore, to address this criticism we assessed
the correlation of AAV2 binding with the amount of hepa-
ran sulfate on the cell surface. In particular, 293 cells
showed reduced AAV2 binding, despite the presence of
FIG. 5. Binding of AAV2 to immobilized GAGs. Microtiter wells were
coated with heparin, modified heparin, chrondoroitin sulfate, dextran
sulfate, or heparan sulfate and incubated with iodinated AAV2 (105 cpm
er well), and the amount of virus binding to the solid phase was
alculated. Each bar represents the mean of three measurements. H:
eparin; NDSH, N-desulfated heparin; ODSH, O-desulfated heparin;
DSH, completely desulfated heparin; DS, dextran sulfate; HS, heparin
ulfate; CS-A, B, C, chrondroitin sulfate A, B, C.
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143INTERACTION BETWEEN HEPARAN SULFATE AND AAV2comparable levels of heparan sulfate detected by the
four monoclonal antibodies.
Generally, hematopoietic cells express less heparan
sulfate on the cell surface than epithelial or fibroblast
cells; in our studies we could detect all four heparan
sulfate epitopes on K562, TF-1, CESS, and Raji cells.
Heparan sulfate expression on hematopoietic cell lines,
including K562, TF-1, and HEL, has also been shown by
the traditional methods of proteoglycan isolation (Drze-
niek et al., 1999; Lefre`re et al., 1999), suggesting that our
low cytometric analysis of heparan sulfate is reliable
nd useful. However, as with the adherent cell lines,
here was no direct correlation between the amount of
eparan sulfate on the cell surface with rAAV2 transduc-
ion or AAV2 binding, although cells with less heparan
ulfate (scoring 11 or less with all four antibodies) were
nable to be transduced with rAAV2. Only one hemato-
oietic cell line that did not express heparin or heparan
ulfate, MO7e cells, was found.
Certain heparin-binding proteins or viruses bind to
pecific saccharide sequences or epitopes on heparin/
eparan sulfate, and this can be blocked by antibody
inding (Ianelli et al., 1998). One monoclonal, mAb570
an autoantibody derived from a MRL mouse, clone 7.2 in
illit et al. (1996)), was able to partially inhibit rAAV
ransduction in blocking studies. This antibody binds to
n epitope on heparin and inhibits the heparin acceler-
ted thrombin–antithrombin complex formation in vitro
Chemicon International, Inc., Temecula, CA). Even
FIG. 6. Heparin affinity binding to AAV2. Microtiter wells were coated
odinated AAV2 in the presence or in the absence of non-iodinated viru
ounting the radioactivity of the whole well. (F) Total binding, (n ) nonsphough heparin is not present on cell surfaces, the
pitope recognized by mAb570 was detected on many ofhe tested cell lines, and the ability to block rAAV2 trans-
uction suggests that this epitope may be involved in the
nteraction of AAV2 and attachment.
Similarly, the observation that removal of either or both
- or N-sulfate groups resulted in a decreased ability to
lock AAV2 transduction and/or binding suggests that
ull sulfation of heparin seems to be required for the
nteraction and that AAV2 may require a combination of
oth types of sulfate group for an efficient interaction
ith heparin/heparan sulfate. This theory was further
upported by the effect of chlorate treatment reducing,
ut not completely abolishing, AAV2 binding and the
orresponding rAAV-LacZ transduction efficiency. How-
ver, it appears that although the sulfate moieties on
eparan sulfate are involved in AAV2 entry, AAV2 may
se an alternative means of cell entry in the absence of
ulfation. Together, these results are comparable to what
as been reported for both herpes simplex virus (Herold
t al., 1995) and vaccinia virus (Chung et al., 1998). It has
een shown that the interaction of many proteins, includ-
ng viruses, with heparan sulfate proteoglycan occurs
argely through electrostatic interactions, with positively
harged arginine and lysine side chains interacting with
he negatively charged sulfates (Fromm et al., 1995). The
AV2–heparan sulfate interaction is presumably similarly
ediated, as the highly sulfated heparin was the most
ffective substrate for binding, suggesting that the de-
ree of sulfation, more than the polysaccharide back-
one, was the critical determinant for binding.
eparin-conjugated BSA and incubated with different concentrations of
the wells were washed with PBST, binding was directly measured by
binding, () specific binding. Scatchard analysis is shown as an inset.with hThe binding affinity (K d) of AAV2 to heparin of ;2 nM
should be compared to the K ds of other heparin/mole-
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144 QIU ET AL.cules or virus interaction. The high-affinity receptor for
bFGF has a K d of 2–10 pM, and the low-affinity receptor
has a K d of 2 nM (Moscatelli, 1987). Other viruses that
se heparan sulfate as an attachment molecule have a
imilar binding affinity for heparin: HIV gp120 binding has
K d of 10 nM (Harrop and Rider, 1998) and dengue virus
has a K d of 15 nM (Chen et al., 1997). However, for HIV,
t is known that heparan sulfate acts only as an attach-
ent molecule, with CD4 and CCR acting as the high-
ffinity receptor and coreceptor, respectively (Sattentau
t al., 1986; Choe et al., 1996; Deng et al., 1996). Similarly,
or many years it was thought that heparan sulfate was
he receptor for HSV. However, recently, several high-
ffinity protein receptors have been identified, e.g., HveC
Montgomery et al., 1996) and poliovirus receptor-related
rotein 1, PvrI (Geraghty et al., 1998; Cocchi et al., 1998).
Together with the evidence that the diversity in the
mount and structure of heparan sulfate on different
ells do not correlate with specific binding and transduc-
ion of AAV2, that cell desulfation does not absolutely
educe the infection, and that the mutant heparan sul-
ate-free CHO cells can still be infected by AAV2, we
elieve that a high-affinity protein receptor must play a
ole in AAV2 infection. Recently, integrin aVb5 (Summer-
ford et al., 1999) and FGFR (Qing et al., 1999) were
proposed as a coreceptors with heparan sulfate for AAV2
infection. However, we have been unable to confirm the
direct interaction of aVb5 with AAV2, and purified aVb5
nd related molecules do not block AAV2 infection, sug-
esting that aVb5 is not essential for AAV2 infection (Qiu
and Brown, 1999b). The role of FGFR is similar to that
previously hypothesized for HSV (Kaner et al., 1990).
owever, subsequent research has shown that FGFR is
ot required in HSV infection (Muggeridge et al., 1992);
he viral inhibiting properties of FGF are due to compe-
ition with binding to the cell surface heparan sulfate,
nd cell lines that do not have FGFR on their cell surface
i.e., Hep-2, and A431) are fully susceptible to HSV infec-
ion. We have demonstrated that the same cell lines
acking FGFR are still able to be infected with AAV2
fficiently (Qiu et al., 1999). A 150-kDa AAV2-binding cell
embrane protein had also been identified (Mizukami et
l., 1996), and this protein possesses potential charac-
eristics as a receptor for AAV2 infection. A high-affinity
eceptor for AAV2 remains to be identified. In contrast,
eparan sulfate appears to facilitate and enhance AAV2–
ell interactions, but is neither sufficient nor necessary
or infection.
MATERIALS AND METHODS
eparin, heparan sulfate, and related molecules
Heparin (H3393), heparin-conjugated bovine albumin,
nd dextran sulfate (500 kDa, 17% sulfation) were ob-ained from Sigma (St. Louis, MO). Chondroitin sulfate B
from bovine mucosa) was purchased from Fluka
b
wRonkonkoma, NY). Heparan sulfate (from bovine kidney),
hondroitin sulfate A (from sturgeon notochord) and C
from shark cartilage), N-desulfated heparin (NDSH;
0.2% N-sulfation, .8.0% sulfation), O-desulfated hepa-
in (ODSH; .4.5% N-sulfation, 4.5–7.0% sulfation), and
oth N- and O-desulfated heparin (CDSH; ,0.1% N-sul-
ation, 1.5% sulfation) were purchased from Seikagaku
merican Co. (Ijamsville, MD).
ell lines
All cell lines, except MO7e cells, were purchased from
TCC (Manassas, VA). Hematopoietic cell lines (HL60,
937, KG-1, KG1a, K560, HEL, MEG-O1, Molt-3, Jurkat,
aji, CESS, CEM, RS, and D1.1) were cultured in RPMI
640; MO7e and TF-1 cells were maintained in RPMI
640 supplemented with 1 U GM-SCF/ml (Life Technol-
gies, Gaithersburg, MD). Adherent cell lines (KB, 293,
eLa, Hep-2, and A431) were maintained in Dulbecco’s
EM; CHO-K1 and CHO mutant cell lines were main-
ained in F12 medium. Suspension cultures of HeLa S3
ere maintained in F12 medium and separately cultured
n either a spinner or a standard flask used for adherent
ultures. All the media were supplemented with 10% fetal
alf sera and penicillin/streptomycin antibiotics; cells
ere incubated at 37°C under 5% CO2.
ecombinant AAV transduction
GFP-recombinant AAV2 (rAAV-GFP) was prepared us-
ng a standard two-plasmid transfection method, with a
AAV-2 packaging vector (pAAV-2-pac) containing the
hole protein coding sequence of AAV-2 subcloned into
he XbaI sites of pBluescript (Stratagene, La Jolla, CA).
he pAAV2-GFP-neo plasmid was constructed using
Sub201 (a gift from Dr. Jude Samulski (Samulski et al.,
989)), with replacement of the coding sequence of
AV-2 by an enhanced humanized GFP and neomycin-
esistance cassette. Both plasmids (10 mg) were cotrans-
ected into Cos-7 cells (106 cells in 400 ml) by electropo-
ration (170 eV, 500 F; Gene Pulser, Bio-Rad, Hercules,
CA). Twenty-four hours later, the cells were infected with
adenovirus type 5 (m.o.i. 5 5). They were harvested 40 h
after adenoviral infection: the monolayer was washed,
and adherent cells were dislodged by scraping, resus-
pended in phosphate-buffered saline (PBS) and lysed by
six cycles of freezing and thawing. After ultrasonication,
sodium deoxycholate was added to a final concentration
of 0.5% and allowed to incubate for 30 min at 37°C. CsCl
was added to a density of 1.4 g/cm3, and rAAV and
adenovirus were separated by two rounds of ultracen-
trifugation at 35,000 g for 40 h, followed by dialysis
against PBS for 24 h to remove CsCl. The final prepara-
tion contained 2 3 1011 genome copies (gc)/ml. Recom-
binant AAV2 encoding the b-galactosidase gene driveny the CMV promoter/enhancer sequence (rAAV-LacZ)
as provided by Avigen International Inc. as a purified
cr
i
w
A
P
t
w
b
s
t
A
I
a
w
c
(
G
a
w
1
p
w
s
t
b
c
t
145INTERACTION BETWEEN HEPARAN SULFATE AND AAV2preparation with 6.5 3 1011 gc/ml. The infection titer (moi)
was estimated by infecting 293 or Cos cells with a serial
dilution of AAV vectors stock and determining the per-
centages of positive cells; the infectious titer for rAAV-
LacZ stock is 3.0 3 107 infectious particles/ml and for
rAAV-GFP equals 2.7 3 107 infectious particles/ml on 293
ells.
Cells (5 3 104) in microtiter wells were infected with
AAV-GFP (m.o.i. 5 2.7) or rAAV-LacZ (m.o.i. 5 3.0) and
ncubated for 48 h. For rAAV-LacZ transduction, cells
ere fixed with 2% glutaraldehyde in PBS and b-galac-
tosidase stained (Beta-gal staining kit, Panvera Corp.,
Madison, CA), and the positive cells were counted. GFP
r-AAV transduced cells were counted directly by UV mi-
croscopy.
Detection of heparan sulfate proteoglycans on the
cell surface
Monoclonal antibodies against heparin and/or hepa-
ran sulfate were obtained from a variety of sources
(Table 1). Antibody mAb615 (provided by Dr. David A.
Thorley-Lawson (Ianelli et al., 1998)) was purified from
ascites (ImmunoPure IgM purification kit, Pierce Co.,
Rockford, IL). Cells (106) were incubated with monoclonal
or isotype control antibody (50–100 mg/ml) in 100 ml of
PBS with 1% BSA for 30 min on ice, washed thoroughly
with PBS–1% BSA, and reincubated with FITC-conju-
gated secondary antibody (Biosource International Inc.,
Camarillo, CA) at 1:50 for a further 30 min. Cells were
washed thoroughly, stained with propidium iodide at 10
mg/ml to exclude nonviable cells, and analyzed by flow
cytometry.
AAV2 binding to cells
Wild-type AAV2 was prepared as previously described
(Qiu and Brown, 1999) and purified by three successive
bandings on CsCl ultracentrifugation, and AAV2 protein
content was measured (BCA protein assay kit, Pierce
Co.). The purified AAV2 preparation was checked to be
adenovirus- and nucleolin-free by Western blotting. The
number of viral particles was calculated based on the
known molecular weight of AAV2 virions (1 mg AAV2 5
1.5 3 1011 viral particles).
A liquid binding assay was performed using iodinated
AV2 as previously described (Mizukami et al., 1996; Qiu
and Brown, 1999). Briefly, cells (105) were washed in
BS–1% BSA, iodinated AAV-2 was added, and the mix-
ure was incubated for 1 h at room temperature. The cells
ere washed three times with PBS–1% BSA, and the
inding was determined by measuring radioactivity. Non-
pecific binding was calculated by measuring binding inhe presence of a 100-fold excess of cold unlabeled
AV2.nhibition of AAV2 infection with glycosaminoglycans
nd monoclonal antibodies
rAAV-LacZ particles (m.o.i. 5 1.5) were preincubated
ith different concentrations of artificial glycosaminogly-
ans at 37°C for 30 min and then added to HeLa cells
5 3 104) plated in microtiter wells. In separate experi-
ments, confluent HeLa cells on microtiter wells were
preincubated with different concentrations of heparan-
specific monoclonal antibodies (mAb570, HepSS-1,
mAb10E4, and mAb615) for 1 h at 37°C, prior to infection
with rAAV-LacZ (m.o.i. 5 1.5), and 48 h later the mono-
layers were b-galactosidase stained and the number of
positive cells was counted.
Removal of cell surface sulfation by sodium chlorate
Desulfation of cells was performed as previously de-
scribed (Chung et al., 1998). Briefly, cells were grown in
96-well plates (5 3 104/well) in sulfate-free Joklik MEM
(Life Technologies) with 1.8 mM CaCl2, 20 mM sodium
chlorate, and 8% dialyzed FCS. As a control, cells were
cultured in the above medium with the addition of 0.8
mM sodium sulfate. Four days later the cells were in-
fected with rAAV-LacZ (m.o.i. 5 1.5), and after a further 2
days culture the cells were examined for b-galactosi-
dase activity.
Solid-phase binding assays
The direct interaction of AAV2 with GAGs (heparin,
modified heparins, dextran sulfate, chondroitin sulfates,
and heparan sulfate) was studied by using heparin and
related molecules directly bound to microtiter plate wells
(Carbo-binding plate, Costar, Cambridge, MA) with the
modification of Byrnes and Griffin (1998). To prepare the
plates GAGs, or BSA for control wells, were diluted in 10
mM sodium acetate buffer (pH 4.0) to a final concentra-
tion of 0.5 mg/ml and activated by the addition of 0.8 mg
NaIO4 per 100 ml for 30 min at room temperature. The
AG mixtures were diluted to 20 mg/ml in 20 mM sodium
cetate buffer (pH 5.5), and 100 ml was used to coat each
ell. The plates were incubated at room temperature for
h, rinsed, and blocked with PBS containing 1% BSA
rior to use.
For the binding assay, prepared plates were incubated
ith 100 ml iodinated AAV2 (105 cpm/well) with constant
haking for 2 h, 50 ml was collected from each well, and
he radioactivity was counted. The amount specifically
ound to each well was calculated by subtraction and
omparison with the resulting radioactivity from that in
he BSA-coated wells.
To estimate the binding affinity (K d value) of AAV2 with
heparin, microtiter plates (Costar) were coated with 100
mg/ml heparin-conjugated BSA (Sigma) in 0.1 M sodium
carbonate buffer, pH 9.6, at 37°C for 1 h. The microtiter
wells were blocked with PBST containing 5% BSA for 1 h
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146 QIU ET AL.at 37°C, washed three times with PBST, and incubated
with iodinated AAV2 in binding buffer (PBST with 1% BSA)
for 2 h at room temperature with constant shaking. The
wells were washed four times with PBST, and the whole
well was used for measuring bound radioactivity. Non-
specific binding was determined by measuring the ra-
dioactivity of identical iodinated AAV2 samples in the
presence of a 100-fold excess of unlabeled AAV2.
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